申请人:——
公开号:US20030109518A1
公开(公告)日:2003-06-12
The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I:
1
or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:
X and Y are independently —C(O)—, —CH
2
— or —C(S)—;
R
1
, R
2
, R
3
, R
4
, R
7
, R
8
, R
b
, R
c
, R
d
and M are defined herein;
R
5
is hydrogen, alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaralkyl, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl or alkylaminocarbonylalkyl;
R
6
is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted;
R
9
is cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkyl(alkyl), aralkyl or heteroarylalkyl, each of which is optionally substituted; and
R
10
is —(CH
2
)
n
—CO
2
R
b
, —(CH
2
)
m
—CO
2
M, —(CH
2
)
i
—OH or —(CH
2
)
j
—CONR
c
R
d
n is 0-8, m is 0-8, i is 1-8 and j is 0-8.
本发明涉及新型1,4-苯二氮平化合物,其药物组合物以及作为H
DM2-p53相互作用
抑制剂的用途。化合物具有公式I:1或其溶剂化物,
水合物或药学上可接受的盐;其中:X和Y独立地为—C(O)—,—
CH2—或—C(S)—;R1、R2、R3、R4、R7、R8、Rb、Rc、Rd和M在此定义;R5为氢,烷基,环烷基,可选取代芳基,可选取代杂环芳基,可选取代芳基烷基,可选取代杂环芳基烷基,羧基烷基,烷氧羰基,烷氧羰基烷基,
氨基羰基,
氨基羰基烷基,烷基
氨基羰基或烷基
氨基羰基烷基;R6为环烷基,芳基,杂环芳基,环烷基烷基,芳基烷基,杂环芳基烷基或饱和或部分不饱和杂环,每个都可以选择性地取代;R9为环烷基,芳基,杂环芳基,饱和或部分不饱和杂环,环烷基(烷基),芳基烷基或杂环芳基烷基,每个都可以选择性地取代;R10为—( )n—CO2Rb,—( )m—CO2M,—( )i—OH或—( )j—CONRcRd,其中n为0-8,m为0-8,i为1-8,j为0-8。